HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia

Ernesto Martínez Buitrago 1,2*, José Millán Oñate 1,3, José Fernando García-Goez 1,4, Jorge Álvarez 1,2, William Lenis 1,5, Luz Marina Sañudo 1 and Luisa Consuelo Rubiano 1,6

Abstract

Background: The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir. Due to the lack of knowledge of HLA-B*57:01 prevalence in Colombia, routine screening is not performed and is not recommended by the national guidelines. We aimed to determine the prevalence of HLA-B*57:01 in HIV population from Colombia.

Methods: This cross-sectional study included naïve HIV-infected adults from 13 cities of the country. The presence of HLA-B*57:01 was determined by using SSP-PCR in blood samples. Prevalence rates were stratified by sex, race, and region of origin.

Results: HLA-B*57:01 allele prevalence in Colombian HIV-infected individuals was 2.7%. When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. The prevalence varied from 0% up to 11.4% depending on the department of origin. The highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). When distributed by country zones, the central, with a racial predominance of Caucasians and mestizos, was the highest (6.0%, OR = 4.1, CI 1.2–12.8, p = 0.016).

Conclusions: The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.

Keywords: Abacavir, Antiretroviral therapy, HLA-B*57:01, HIV infection, Hypersensitivity, Pharmacogenetics. Cross-sectional study

Background

Abacavir, a nucleoside reverse transcriptase inhibitor (NRTI), is an antiretroviral agent frequently used as part of combination therapy for human immunodeficiency virus (HIV) infection. It is part of the first-line treatment regimens in HIV guidelines worldwide [1–3]. Although abacavir demonstrates a favorable safety profile with fewer long-term toxicities in contrast to most other NRTIs, a potentially severe hypersensitivity reaction (HSR) to abacavir has been described and strongly associated with the presence of human leukocyte antigen (HLA)-B*57:01 allele [4–6]. HSR is characterized by the presence of constitutional symptoms (fever, malaise, headache, myalgia), rash, gastrointestinal symptoms (vomiting, diarrhea), and respiratory symptoms (cough, dyspnea). These symptoms usually worsen following each consecutive dose with the risk of death if the drug is not stopped early [6, 7]. Clinical manifestations usually disappear two days after drug discontinuation. Re-exposure to abacavir could lead to severe clinical forms complications as anaphylactic reaction and death [7, 8].

* Correspondence: emarbui@gmail.com; ernestomartinez@correounivalle.edu.co
This work was presented as a poster at the 20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, New York, October 13-14, 2018, Abstract 22
1Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia
2Universidad del Valle, Cali, Colombia
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
HSR to abacavir occurs within six weeks of the initiation of treatment in over 90% of cases [7, 8]. The risk of developing HSR is lower among Afro-descendants, male sex, those treatment-experienced, and those with advanced HIV disease or CDC stage C (likely more experienced and therefore potentially more tolerant) [9–11]. Abacavir-related HSR had an incidence of about 5% (range 0–14%), and a mortality rate of 0.03% before the significant association with HLA-B*57:01 was established, and pretreatment genetic screening was employed [4, 8–10, 12–18]. In 2008, the PREDICT-1 study demonstrated the effectiveness of prospective HLA-B*57:01 screening in preventing abacavir-related HSR, with positive and negative predictive values of 58 and 100%, respectively [14]. Since then, current international HIV treatment guidelines recommend HLA-B*57:01 screening in HIV-infected patients at diagnosis or before initiating abacavir-containing regimens if previously unknown. Consequently, the occurrence of abacavir-related HSR has been reduced to 0–3% due to the exclusion of abacavir use in high-risk population [6, 14–18].

Prevalence of HLA-B*57:01 allele is variable among different racial and ethnic populations across the world. The Caucasians have higher prevalence rates of HLA-B*57:01 (4–8%) than African-Americans, Asians, and Hispanics (0.2–4%) [6, 14–22]. In Latin America, a few studies performed in Argentina, Brazil, Chile, Costa Rica, and Mexico have estimated the prevalence of HLA-B*57:01 allele between 2 and 5.6% among HIV-infected patients [12, 23–27]. In Colombia, however, there are no data regarding the prevalence of HLA-B*57:01 allele and current national guidelines do not consider HLA-B*57:01 screening in HIV-infected patients [3]. Colombia is a country with marked racial and ethnic differences across its geography making challenging to estimate the allele prevalence based on neighboring countries reports from the region leading this to uncertainty in the safety of the use of abacavir.

Further, the use of this pharmacogenetic test is limited by its availability and cost. The Colombian national guidelines for the management of HIV in adults and adolescents recommend the use of abacavir/lamivudine plus efavirenz as the first-line therapy and the most cost-effective regimen: however, screening for the HLA-B*57:01 allele before the initiation of treatment is not recommended for the absence of evidence-based data. Therefore, we conducted a nationwide cross-sectional study to determine the prevalence of HLA-B*57:01 allele in antiretroviral treatment-naïve HIV population from Colombia.

Methods

Study design and population

We conducted a nationwide, multicenter, cross-sectional study which recruited HIV-infected patients receiving medical care in 14 centers for HIV comprehensive care from 13 Colombian cities (Bogotá, Medellín, Cali, Barranquilla, Montería, Cartagena, Bucaramanga, Cúcuta, Pereira, Villavicencio, Manizales, Florencia, and Pasto). From July 2017 to March 2018, treatment-naïve HIV-positive patients aged 18 years or older were consecutively included in the study, regardless of the clinical stage of HIV infection, lymphocyte (LT) CD4+ cell count or HIV viral load, time of diagnosis. We exclude patients on antiretroviral treatment or had been previously treated to avoid selection bias. All patients had been previously confirmed for HIV infection employing immunoenzymatic assays, HIV rapid tests, or Western blot tests, as defined and recommended by the clinical practice guidelines of the Colombian Ministry of Health and Social Protection and the Colombian Association of Infectious Diseases (ACIN) [3].

Sample selection

The sample size was calculated using the proportion formula for finite populations based on an expected HLA-B*57:01 prevalence of 3% +/- 1%, an estimated population of 6000 people, a 95% confidence level, and an additional 2% to prevent patient loss. The minimum number of patients needed to estimate the prevalence of the allele was calculated as 961 patients. The cities and the corresponding sample size were defined for this study according to the regional prevalence known for Colombia for the year 2016. These cities have a population of diverse racial background and accounted for around 80% of the HIV population according to data from the Colombian non-governmental organization Cuenta de Alto Costo (CAC) [28]. Colombians are descendant from three racial groups (Caucasians, Africans, Amerindians). The ethnic composition of the Colombian population is an admixture estimated to result in mestizo (50%), Caucasian (25%), mulatto and Zambo (20%), afro-Colombian (4%), and indigenous (1%) [29].

Data collection

Data collectors were the professionals in each institution in charge of recruiting the participants. They were trained to fill out a standardized form containing sociodemographic and clinical data, including sex, age, race, the department of origin, time since HIV diagnosis, baseline LT CD4 cell count, baseline HIV viral load, and CDC clinical stage at diagnosis. Each patient had a unique identification code used for both the case report form, and the label for a 5-mL blood sample collected after obtaining written informed consent.

Patient race was classified into four groups, Caucasians, mestizos, Afro-Colombian, and indigenous, considering the characteristics recommended in public health in Colombia, which included: characteristics of the hair, facial features, skin color, self-recognition and place of birth. The departments of origin were classified in the following zones: the
Northern zone with predominance of Afro-Colombians and mestizos (departments of Atlántico, Bolívar, Sucre, Magdalena, Córdoba, Cesar, and Norte de Santander); the Central zone with predominance of Caucasians and mestizos departments of Antioquia, Caldas, Risaralda, and Quindío; The Western zone, predominance of Afro-Colombians and mestizos (departments of Chocó, Cauca, Nariño, and Valle); the Eastern (departments of Arauca, Caquetá, Casanare, Guaviare, Meta) and the Andean zones (Bogotá Distrito Especial, and departments of Cundinamarca, Huila, Tolima, Boyacá, and Santander) both with predominance of mestizos.

Laboratory procedures
In two molecular biology laboratories (Primed Laboratory in Barranquilla and Laboratorio de Genética y Biología Molecular in Bogotá), blood samples were screened for HLA-B*57:01 carriage by using allele and group-specific polymerase chain reaction-sequence-specific primers (PCR-SSP) typing. This technique has been previously validated to be a reliable method of distinguishing between HLA-B*57:01 and other commonly occurring -B*57:02 and -B*57:03 alleles, with a sensitivity of 99.4 and 100% in two different studies, and specificity of 100% in both [30–32].

Statistical analysis
Data describing clinical and demographic patient characteristics were summarized using medians with interquartile ranges (IQR) for continuous variables and frequencies and proportions for categorical variables. Data were entered into EpiInfo 6.04 (Centers for Disease Control and Prevention, Atlanta, USA) and then exported to Stata version 12.0 (StataCorp, College Station, TX, USA) for analysis statistical comparisons of patient characteristics by HLA-B*57:01 were made with logistic regression to evaluate the significance of differences in allelic frequencies between sex, ethnicity, and places of residence.

Results
After exclusion of 60 patients due to missing data, a total of 902 HIV-infected patients were included in the study, of which 750 (83.1%) were male (Table 1).

### Table 1 Demographic, clinical and laboratory characteristics of HIV-infected patients included in the study and those positive for HLA-B*5701 allele (Continued)

| Variable                          | Total       | HLA-B*5701-positive | p   |
|-----------------------------------|-------------|---------------------|-----|
| **Race**                          |             |                     |     |
| Afro-Colombian                    | 54 (6.0%)   | 1 (4.2%)            | 0.58|
| Caucasian                         | 50 (5.5%)   | 2 (8.3%)            | 0.39|
| Indigenous                        | 5 (0.6%)    | 0 (0%)              | 0.87|
| Mestizo                           | 793 (87.9%) | 21 (87.5%)          | 0.57|
| **Region of origin**              |             |                     |     |
| Andean                            | 259 (28.7%) | 4 (16.7%)           | 0.14|
| North                             | 226 (25.1%) | 2 (8.3%)            | 0.04|
| Central                           | 200 (22.2%) | 12 (50%)            | 0.003|
| Western                           | 169 (18.7%) | 5 (20.8%)           | 0.48|
| Eastern                           | 48 (5.3%)   | 1 (4.2%)            | 0.63|
| **Time since HIV diagnosis (days)**|          |                     |     |
| Median (IQR)                      | 36 (21–74)  | 67 (28–429)         | 0.31|
| ≤ 30                              | 367 (40.7%) | 8 (33.3%)           | 0.31|
| 31–180                            | 414 (45.9%) | 6 (25%)             | 0.03|
| 181–360                           | 39 (4.3%)   | 3 (12.5%)           | 0.09|
| 361–720                           | 30 (3.3%)   | 3 (12.5%)           | 0.05|
| > 720                             | 52 (5.8%)   | 4 (16.7%)           | 0.05|
| **Baseline CD4 cell count (cells/mm³)** |     |                     |     |
| Median (IQR)                      | 321 (177–504)| 450 (360–638)     |      |
| ≤ 200                             | 257 (28.4%) | 2 (8.4%)            | 0.02|
| 200–499                           | 419 (46.5%) | 11 (45.8%)          | 0.56|
| ≥ 500                             | 226 (25.1%) | 11 (45.8%)          | 0.02|
| **Baseline HIV viral load (copies/mL)** |     |                     |     |
| Median (IQR)                      | 44,332 (11206–156,278)| 9064 (2749–22,248) |      |
| ≤ 40                              | 14 (1.5%)   | 2 (8.3%)            | 0.06|
| 40–1000                           | 48 (5.3%)   | 3 (12.5%)           | 0.14|
| 1001–1,000                        | 145 (16.1%) | 9 (37.5%)           | 0.01|
| 10,001–100,000                    | 391 (43.4%) | 8 (33.3%)           | 0.22|
| > 100,000                         | 304 (33.7%) | 2 (8.3%)            | 0.004|

Northern zone with predominance of Afro-Colombians and mestizos (departments of Atlántico, Bolívar, Sucre, Magdalena, Córdoba, Cesar, and Norte de Santander); the Central zone with predominance of Caucasians and mestizos departments of Antioquia, Caldas, Risaralda, and Quindío; The Western zone, predominance of Afro-Colombians and mestizos (departments of Chocó, Cauca, Nariño, and Valle); the Eastern (departments of Arauca, Caquetá, Casanare, Guaviare, Meta) and the Andean zones (Bogotá Distrito Especial, and departments of Cundinamarca, Huila, Tolima, Boyacá, and Santander) both with predominance of mestizos.

Data describing clinical and demographic patient characteristics were summarized using medians with interquartile ranges (IQR) for continuous variables and frequencies and proportions for categorical variables. Data were entered into EpiInfo 6.04 (Centers for Disease Control and Prevention, Atlanta, USA) and then exported to Stata version 12.0 (StataCorp, College Station, TX, USA) for analysis statistical comparisons of patient characteristics by HLA-B*57:01 were made with logistic regression to evaluate the significance of differences in allelic frequencies between sex, ethnicity, and places of residence.

Results
After exclusion of 60 patients due to missing data, a total of 902 HIV-infected patients were included in the study, of which 750 (83.1%) were male (Table 1).
median age was 29 years (interquartile range, IQR 24–39). The median time since diagnosis was 36 days (IQR 21–74). The median baseline LT CD4+ cell count and HIV viral load were 321 cells/mm3 and 44,332 copies/mL, respectively. The HLA-B*57:01 allele was found in 24 patients accounting for an overall prevalence of 2.7% (2.7% in men and 2.6% in women, \( p = 0.62 \)) (Table 2). When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. Statistically higher positivity rates for the HLA B*57:01 allele were found among subjects with higher LT CD4 count, lower viral load, clinical

### Table 2: Prevalence estimates for HLA-B*5701-positive stratified by sex, race, and region of origin

| Variable                        | n    | HLA B*5701 + (n) | Prevalence (%) | OR* | IC - 95%     | p    |
|---------------------------------|------|------------------|----------------|-----|-------------|------|
| Overall                         | 902  | 24               | 2.7            |     |             |      |
| Race                            |      |                  |                |     |             |      |
| Mestizo                         | 793  | 21               | 2.6            | 1.0 |             |      |
| Afro-Colombian                  | 57   | 1                | 1.8            | 0.7 | 0.09–5.26   | 0.72 |
| Caucasian                       | 50   | 2                | 4.0            | 1.5 | 0.35–6.72   | 0.57 |
| Indigenous                      | 5    | 0                |                |     |             |      |
| Country zones and departments of origin |      |                  |                |     |             |      |
| Andean zone**                   | 259  | 4                | 1.5            | 1.0 |             |      |
| Bogotá                          | 126  | 3                | 2.4            | 0.7 | 0.07–7.04   | 0.77 |
| Cundinamarca                    | 42   | 0                |                |     |             |      |
| Tolima**                        | 30   | 1                | 3.3            | 1.0 |             |      |
| Santander                       | 29   | 0                |                |     |             |      |
| Boyacá                          | 23   | 0                |                |     |             |      |
| Huila                           | 9    | 0                |                |     |             |      |
| Central zone                    | 200  | 12               | 6.0            | 4.1 | 1.2–12.8    | 0.016|
| Antioquia                       | 140  | 7                | 5.0            | 1.5 | 0.18–12.9   | 0.69 |
| Caldas                          | 35   | 4                | 11.4           | 3.7 | 0.39–35.5   | 0.25 |
| Risaralda                       | 21   | 1                | 4.8            | 1.5 | 0.09–246    | 0.79 |
| Quindío                         | 4    | 0                |                |     |             |      |
| Western zone                    | 169  | 5                | 2.9            | 1.9 | 0.51–7.3    | 0.327|
| Valle                           | 118  | 5                | 4.3            | 1.3 | 0.14–11.4   | 0.82 |
| Cauca                           | 41   | 0                |                |     |             |      |
| Nariño                          | 8    | 0                |                |     |             |      |
| Chocó                           | 2    | 0                |                |     |             |      |
| North zone                      | 226  | 2                | 1.8            | 0.6 | 0.10–3.13   | 0.518|
| Atlántico                       | 87   | 1                | 1.1            | 0.3 | 0.02–5.56   | 0.45 |
| Norte de Santander              | 65   | 1                | 1.5            | 0.5 | 0.03–7.49   | 0.58 |
| Bolivar                         | 35   | 0                |                |     |             |      |
| Magdalena                       | 15   | 0                |                |     |             |      |
| Córdoba                         | 13   | 0                |                |     |             |      |
| Sucre                           | 6    | 0                |                |     |             |      |
| Cesar                           | 5    | 0                |                |     |             |      |
| Eastern zone                    | 48   | 1                | 2.1            | 1.3 | 0.14–12.4   | 0.787|
| Meta                            | 33   | 1                | 3              | 0.9 | 0.05–15.16  | 0.95 |
| Caquetá                         | 10   | 0                |                |     |             |      |
| Arauca                          | 2    | 0                |                |     |             |      |
| Casanare                        | 2    | 0                |                |     |             |      |
| Guaviare                        | 1    | 0                |                |     |             |      |

*Logistic regression **Reference category
stages A and B, and lower for those with an LT CD4 < 200 cells/mm³ and viral load > 100,000 copies/mL (Table 1). The country geographic five zones were mostly evenly represented in the sampled population, except for the Eastern zone that only had 5.3% (n = 48). The prevalence varied from 0% up to 11.4%, the highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). Eighteen of the 26 regions of origin in our study population had a null prevalence. Also, when grouped by zones of the country, the prevalence ranged from 0.9% in the North Zone to 6.0% in the Central zone (Table 2, Fig. 1).

The logistic regression analysis did not show any statistical association between demographic, racial, and geographical characteristics with the presence of the allele HLA-B*57:01. However, attention is drawn to the OR of the group defined as Caucasian (OR: 1.5), which loses significance due to the size of the subgroup (p = 0.57). On the other hand the geographical distribution according to the region where the individual was born, gains significance.

![Prevalence of HLA-B*5701 Carriers In Naïve HIV-1 Infected Individuals in Colombia, by Geografic Zone (lighter color) and Department of Origin (darker color)](image)

**Table 3** HLA-B*5701 prevalence studies conducted in different regions across the world

| Country, publication year | Number of subjects | Prevalence | HLA-B*5701 screening recommendation | Reference |
|--------------------------|--------------------|------------|-----------------------------------|-----------|
| Australia, 2006          | 260                | 7.7%       | Yes                               | [15]      |
| Taiwan, 2007             | 320                | 0.3%       | No                                | [18]      |
| 19 countries, 2008       | 1956               | 5.6%       | Yes                               | [14]      |
| Chile, 2010              | 492                | 2.2%       | Yes                               | [23]      |
| México, 2011             | 300                | 2%         | Yes                               | [24]      |
| Brazil, 2011             | 96                 | 3.1%       | Yes                               | [26]      |
| Brazil, 2014             | 517                | 5.6%       | Yes                               | [12]      |
| Costa Rica, 2014         | 200                | 5%         | Yes                               | [25]      |
| Argentina, 2015          | 1646               | 4.9%       | Yes                               | [27]      |
| Iran, 2016               | 198                | 3%         | HLA-B*5701 may reduce risk, but there are cost issues | [22] |
| USA, 2017                | 385                | 3.4%       | Yes                               | [21]      |
and confirms the tendency of the Caucasian group to show the OR: 4.1 with \( p = 0.016 \) for the Central area where the Caucasian ethnic group predominates, in the departments of Antioquia, Caldas, Risaralda, and Quindío (Table 2).

**Discussion**

HLA-B*57:01 is a genetic marker of clinical importance that has been successfully used in several other countries, resulting in a significant decrease of abacavir-related HSR (56–100%) [14–17, 33, 34]. Ideally, since HLA-B*57:01 prevalence varies among different populations, it is essential to ascertain HLA-B*57:01 prevalence before implementing a genetic screening recommendation in a given population.

In our study, we screened Colombian HIV-infected treatment naïve patients for HLA-B*57:01 carriage. We estimated an overall HLA-B*57:01 prevalence rate of 2.7%, being lower than the reported rates for other Latin American countries such as Brazil (3.1–6.6%, \( p = 0.49 \) and 0.004, respectively) [12, 26], Costa Rica (5%, \( p = 0.07 \) [25], and Argentina (4.9%, \( p = 0.003 \) [27], but similar to those found in Chile (2.2%, \( p = 0.38 \) [23] and Mexico (2%, \( p = 0, 34 \) [24]. The heterogeneity in HLA-B*57:01 frequency underscores the need for local studies in countries, especially those belonging to such a genetically diverse region like Latin America, as even populations with similar ancestry backgrounds might differ significantly [35]. The fact that HLA-B*57:01 prevalence for Colombia is intermediate between the frequencies reported for Caucasians and Afro-descendants is likely due to the admixture of genetic and racial backgrounds [29]. It is worth noting that consistently in our study, the prevalence rates stratified by race were 4.2 and 1.9% for Whites, other races (mainly mestizo), and Afro-Colombians, respectively. We found a high variability of the frequency of HLA-B*57:01 among the study regions. The lowest prevalence was observed in Atlántico (1.1%) in the Northern zone and the highest in Caldas (11.4%) in the Central zone. The North zone had the lowest rate (0.9%), with sizeable African origin inheritance, and the Central zone the highest (6.0%), with Caucasian and mestizo race predominance. While the heterogeneity of HLA-B*57:01 prevalence is mostly dependent upon the race and ethnicity heritage [6, 14–22], there are no other related factors drawn from our study data to explain the difference in the HLA-B*57:01 allele prevalence rates.

Colombia is a country with high use of abacavir-containing regimens as first-line or treatment switch (about 31%) [28], but HLA-B*57:01 is rarely performed in clinical practice. Our findings on the prevalence rates of HLA-B*57:01 confirm a substantial proportion of HLA-B*57:01 carriers in Colombia and represent the first step towards the routine genetic screening for the presence of this allele in Colombia as a measure to prevent abacavir-related HSR. Several studies elsewhere have reported HLA-B*57:01 prevalence rates from 0.3 to 7.7%, with most of them recommending screening in HIV-infected patients before using abacavir (Table 3) [12, 14, 15, 18, 21–27]. Remarkably, it must be noted that HLA-B*57:01 screening, although highly specific, never substitutes for clinical follow-up of patients starting abacavir-containing regimens [19, 36].

Our study had a few limitations. First, some geographic HLA-B*57:01 estimates might be over- or underestimated due to the low number of patients reported for some regions of origin. Second, HLA-B*57:01-negative patients starting abacavir-containing regimens were not followed up; therefore, the incidence of HSR was not assessed.

**Conclusions**

Considering all the evidence favoring HLA-B*57:01 screening elsewhere and our findings, we strongly recommend the implementation of this pharmacogenetic test before prescribing abacavir in the HIV-infected population from Colombia. In order to determine the need for routine evaluation of HLA-B*57:01-positive individuals before initiating abacavir-containing therapy, cost-effectiveness studies could be considered in some regions of the country.

**Abbreviations**

ACIN: Asociación Colombiana de Infectología; CAC: Cuenta de Alto Costo; CDC: Centers for Disease Control and Prevention; HIV: Human Immunodeficiency Virus; HLA: Human Leukocyte Antigens; HSR: Hypersensitivity Reaction; IQR: Interquartile Ranges; LT CD4+: Lymphocyte CD4+; NRTI: Nucleoside Reverse Transcriptase Inhibitor; PCR-SSP: Polymerase Chain Reaction-Sequence-Specific Primers

**Acknowledgements**

We would like to thank the following persons in the participating institutions: SIES Salud (Bogotá: Luis F. Echeverría; Cali: Claudia I. González, Kevin Escandón-Vargas; Medellin: María P. Posada; Pereira: Julieta Franco; Florencia: Andrea C. Rodríguez), Recuperar IPS (Cali: Jorge A. Ramírez, William Lenis), CEPAIN (Bogotá: Mónica Mantilla, Leonardo Árvalo; Cúcuta: Javier Stand; Villavicencio: Willmar Tobón; Manizales: Angela Cuartas), Asistencia Científica de Alta Complejidad (Bogotá: Otto Sussmann), Medicina Integral (Gonzalez Hernández; Barranquilla: Pierina Di Ruggiero Pertuz); Oncovida (Barranquilla: Gustavo A. Duncan, Edisson Barrera), CDI S.A. (Olga C. Niño; Bucaramanga: Elsa Rojas Gárrido), Fundación Caminos (Cartagena: Sandra Alandete, Carlos Castañeda).

**Authors’ contributions**

EMB lead the design, development, data analysis and conclusions of the study, was responsible for the writing of the paper, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. JJMO contributed substantially in the design of the study, conduct, analysis and interpretation of the results, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. JFG was responsible for the writing of the paper, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or
integrity of any part of the work. WL contributed substantially in the design of the study, implementation, analysis and interpretation of the results, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. LMS contributed substantially in the implementation of the study, analysis and interpretation of the results, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. LCR made major contributions in the design of the study, analysis and interpretation of the results, has approved the submitted revised version of the manuscript, and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work.

Funding
An unrestricted grant provided the funding for this research from VIIV Healthcare to Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets generated and analyzed during the current study are available in the REVIVA (Red de VIH de Valle del Cauca) repository and are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was conducted according to the Declaration of Helsinki and the national research regulations. The study received approval by the Institutional Review Board of Corporación Científica Pediátrica in Cali, Colombia (reference number CEI-060-2016). All subjects who agreed to participate in the research provided written informed consent to participate.

Consent for publication
No individual patient data is presented, therefore consent to publish was not requested.

Competing interests
EMB reports research grants from VIIV Healthcare/GSK, financial support for REVIVA foundation and VIHCOL Group (Grupo Colombiano de VIH) from GSK, MSD and Stendhal, and personal fees for presentations and advisory board meetings from GSK, MSD and Stendhal and presentations from Janssen Pharmaceuticals. JMO reports grants from VIIV Healthcare/GlaxoSmithKline, and personal fees from Merck Sharp & Dohme Colombia. JFO reports personal fees from Merck Sharp & Dohme Colombia. JA reports grants from VIIV Healthcare/GlaxoSmithKline and grants and personal fees from Merck Sharp & Dohme Colombia. JF reports personal fees from Merck Sharp & Dohme Colombia. EM reports research grants from ViiV Healthcare/GSK, financial support for translation of pharmacogenetics to personalized medicine. SC China Life Sci. 2013;56:119–24.

Author details
1Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia. 2Universidad del Valle, Cali, Colombia. 3Centro Médico Imbanaco, Cali, Colombia. 4Hospital Universitario Fundación Valle del Lili, Cali, Colombia. 5Recuperar SA IPS, Cali, Colombia. 6Pontificia Universidad Javeriana de Cali, Cali, Colombia. 7Universidad Icesi, Cali, Colombia. 8Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia. 9Hospital Universitario Fundación Valle del Lili, Cali, Colombia. 10Hospital Universitario Fundación Valle del Lili, Cali, Colombia. 11Universidad Icesi, Cali, Colombia.

Received: 14 May 2019 Accepted: 27 August 2019

Published online: 09 September 2019

References
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. (Updated 25 October 2018). https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescent.pdf. (2018).
2. European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 9.1, Updated October 2018. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. (2018).
3. Ministry of Health and Social Protection. Evidence-based clinical practice guidelines for HIV infection care of teenagers (12 years old and older) and adults. (2014).
4. Mallal S, et al. HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase. Lancet. 2002;359:1121–2.
5. Hetherington S, et al. Genetic variations in HLA-8 region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–2.
6. Hughes CA, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42:387–96.
7. Clay PG. The abacavir hypersensitivity reactions: a review. Clin Ther. 2002;24:1502–14.
8. Hetherington S, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–14.
9. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38:2171–2.
10. Symonds W, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565–73.
11. Easterbrook P, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir*. HIV Med. 2003;4:321–4.
12. de Araujo C, et al. Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-1 infected individuals in Brazil. Open J Genet. 2014;4:56–62.
13. Carolino F, et al. Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*57:01 allele in a Portuguese HIV-positive population: Porto Biomed. J. 2017;25:59–62.
14. Mallal S, et al. HLA-B*57:01 Screening for Hypersensitivity to Abacavir. N Engl J Med. 2008;12. https://doi.org/10.1056/NEJMoa0706135.
15. Rauch A, et al. Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99–102.
16. Zucman D, de Truchis P, Majerholc C, Stegman S, Callart-Zucman S. Prospective screening for human leukocyte antigen-B*57:01 avoids Abacavir hypersensitivity reaction in the ethnically mixed French HIV population. JAIDS J Acquir Immune Defic Syndr. 2007;45:1–3.
17. Waters. Prospective HLA-B*57:01 screening and ABC hypersensitivity, a single centre experience. (2007).
18. Sun H-Y, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*57:01 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007;60:599–604.
19. Orkin C, et al. An epidemiologic study to determine the prevalence of the HLA-B*57:01 allele among HIV-positive patients in Europe: Pharmacogenet Genomics. 2010;20:307–14.
20. Guo Y, et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci. 2013;56:119–24.
21. Small CB, Margolis DA, Shafer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017;17:12.
22. Baniasadi. Prevalence of HLA-B*57:01 and Its Relationship with Abacavir hypersensitivity, a successful example of translation of pharmacogenetics to personalized medicine. J Pharm Genomics. 2011;12:809–14
23. Anieta-Bolaños E, Madrigal JA, Marsh SGE, Shaw BE, Salazar-Sánchez L. The frequency of HLA-B*57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. Hum Immunol. 2014;75:1092–6.
24. Crovella S, et al. Frequency of HLA-B*57:01 allele carriers in abacavir-treated HIV-infected patients and controls from northeastern Brazil. Clinics. 2011;66:1485–8.
25. Moragas M, et al. Prevalence of HLA-B*57:01 allele in Argentinian HIV-1 infected patients: HLA-B*57:01 in HIV-1 infected patients. Tissue Antigens. 2015;86:28–31.
26. Cuesta de Alto Costa. “Boletín Situación del VIH, Colombia. 2016”. https://cuentadealtocosto.org/site/index.php/publicaciones/hiv. Accessed 1 December 2017.
27. Hanratty, D. M. & Meditz, S. W. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–14.
28. Mallal S, et al. HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase. Lancet. 2002;359:1121–2.
29. Hanratty, D. M. & Meditz, S. W.
30. Martin AM, Nolan D, Mallal S. HLA-B*57:01 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens. 2005;65:571–4.
31. Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens. 2007 Jul;70(1):58–61.
32. Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther. 2007;12(7):1027–32.
33. Phillips, E. J. Genetic screening to prevent Abacavir hypersensitivity reaction: are we there yet? 3 (2006).
34. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1–9.
35. Suarez-Kurtz G, Pena J. S. Pharmacogenomics in the Americas: the impact of genetic admixture. Curr. Drug Targets. 2006;7:1649–58.
36. Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and Abacavir dosing. Clin Pharmacol Ther. 2012;91:734–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.